Global Recombinant DNA Technology Market

Global Recombinant DNA Technology Market Size, Share, Growth Analysis, By Product(Medical (Therapeutic Agent, Human Protein), By Component(Expression System (Mammalian, Bacteria), By Application(Health and disease (Human, Animal)), By End User(Pharmaceutical and biotechnology companies, Research institutes) - Industry Forecast 2024-2031


Report ID: SQMIG35H2067 | Region: Global | Published Date: February, 2024
Pages: 242 | Tables: 124 | Figures: 77

Global Recombinant DNA Technology Market Insights

Recombinant DNA Technology Market size was valued at USD 141.96 billion in 2019 and is poised to grow from USD 152.79 billion in 2023 to USD 274.52 billion by 2031, growing at a CAGR of 7.6% in the forecast period (2024-2031).

The development of recombinant DNA (rDNA) technology has given scientists unprecedented control over genetic data. It is now used in a wide range of applications, including conventional and non-traditional. Without the aid of human donors, recombinant medications and therapeutics have indeed been produced with remarkable success over the past few years.

The commercial success of genetic modification insulin as a diabetes treatment is the classic example of this achievement. The biotech and pharmaceutical industries are exploring how rDNA techniques might be used in various facets of illness management. This is primarily done to combat the rising costs associated with chronic illnesses and stay up with the growing market for therapeutics.

Furthermore, by enabling it possible to produce a recombinant DNA molecule, the gradual development of rDNA techniques has opened up new avenues for improving biopharmaceutical development. The adoption of this technology is expected to be fueled by the presence of a strong biopharmaceuticals pipeline, especially the pipeline for recombinant proteins. The growth of the market is due primarily to the development of recombinant products using rDNA techniques in conjunction with CRISPR/Cas9 nuclease, ZFN, and TALEN enabling simple & precise genome editing with no restriction by organisms. Several review studies carried out by scientists have shown the efficacy of rDNA technology.

The growth of GM crop acreage globally is evidence of this technology's success in the agricultural and food sectors. Its use in other unusual applications, such as the production of biofuel and biopesticides to solve environmental issues, has indeed been inspired by this. Because of the ethical issues in numerous applications, such as gene therapy, the use of this technology has been contentious. Technology and morality have varied, discipline-specific concerns in the diverse fields of agriculture, the environment, and medicine.

US Recombinant DNA Technology Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Recombinant DNA Technology Market size was valued at USD 141.96 billion in 2019 and is poised to grow from USD 152.79 billion in 2023 to USD 274.52 billion by 2031, growing at a CAGR of 7.6% in the forecast period (2024-2031).

These participants are working together in alliances to provide their services in a variety of life science fields. Also, as a realistic tactic to maintain competitiveness in the market, companies are growing constantly their manufacturing facilities. 'Thermo Fisher Scientific Inc.', 'Merck KGaA', 'GenScript Biotech Corporation', 'Horizon Discovery Group plc', 'Lonza Group AG', 'Novartis AG', 'Integrated DNA Technologies, Inc.', 'Genentech, Inc.', 'Amgen Inc.', 'Biogen Inc.', 'Illumina, Inc.', 'Agilent Technologies, Inc.', 'Roche Holding AG', 'Qiagen N.V.', 'Eurofins Scientific SE', 'Takara Bio Inc.', 'Celgene Corporation', 'Bio-Rad Laboratories, Inc.', 'Gensight Biologics S.A.', 'Promega Corporation'

During the forecast period, market expansion is expected to be driven by increasing strategic collaborations between leading market players to advance recombinant DNA technology. To create novel therapeutics based on recombinant DNA technologies, key market players strategically work with large biopharmaceutical companies and research institutions. Such market-wide strategic alliances are anticipated to spur market expansion soon.

A large amount of public acceptance is now being acquired for the development of genetically modified crops in agriculture to increase yield and resistance to herbicides or pesticides. The genetically modified tomato CGN-89564-2 was among the first commercially available genetically engineered crop items to be granted a license for human consumption. Also dependent on DNA molecular marker technologies are the identification, evaluation, mining, and innovation of plant germplasm resources. Thus, it is expected that increasing RDT being used in food and agriculture will drive the original study segment's growth. Research on genetically modified organisms (GMOs), such as that on microorganisms that are regarded as bio degraders and generators of clean fuel, helps a wide range of additional sectors. Numerous human and plant illnesses are treated with genetically modified vaccinations. Recombinant DNA technology has opened up a variety of potential opportunities and prospects for creating a variety of therapeutic items with immediate effects in medical genetics and biomedicine. This is achieved by altering microbes, animals, and plants to produce medically valuable compounds.

North America dominated the global market. The largest portion of the North American continent can be ascribed to the country's high concentration of biopharmaceutical manufacturing companies. Development aid has also been aided by the existence of powerful regulatory bodies that can keep an eye on the numerous ethical and scientific issues raised by the use of technology.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Recombinant DNA Technology Market

Product ID: SQMIG35H2067

$5,300
BUY NOW GET FREE SAMPLE